Why aren't we focusing on T315i?
7,000 EU patients per year times 20% T315i mutation equals 1,400 patients per year. Add another 25% for 3rd line (50% of imatinib R/I times 50% for dasatinib/nilotinib R/I) and you get 3,150 total EU patients per year...eligible now and 100% Iclusig's share of the market. US market share is more like 50% of US population of 2,500 switching TKI's, or 1,250 per year.
In short the EU patient population based on the label is nearly 3 times the US. Of course this assumes we get T315i testing to be standard of care.
